DAX-1,61 % EUR/USD-0,64 % Gold+0,28 % Öl (Brent)+0,57 %

Nanobiotix 2018 Annual Results

Nachrichtenquelle: Business Wire (engl.)
15.03.2019, 19:12  |  223   |   |   

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190315005499/en/

Development Plan

Development Plan

NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited1 consolidated results for the fiscal year ended December 31, 2018:

  • Major milestones achieved during the year:
    • Positive Phase II/III results for NBTXR3 in patients with locally advanced Soft Tissue Sarcoma demonstrating clinical meaningful benefits versus standard of care
    • Positive clinical update from Phase I Head and Neck and Phase I/II Liver cancers trials presented at major congresses
    • Completion of Phase I dose escalation in Head and Neck cancers
    • Engaged major preclinical collaborations with highly respected U.S. cancer centers including the University of Texas MD Anderson Cancer Center, the Providence Cancer Institute and Weill Cornell Medicine
  • Consolidated cash available of €36.2M at December 31, 2018
    • Strengthened by the payment of a €16M first tranche pursuant to a €40M non-dilutive financing agreement established with the European Investment Bank in 2018
  • Expenses in R&D proceeding as expected according to clinical development plan

Philippe Mauberna, Chief Financial Officer of Nanobiotix said: “2018 has been a major year for Nanobiotix, we made significant progress in the financial and clinical plan of the company. R&D expenses are linked to our development plan and the hiring of experts in key positions. We are delighted by the positive results in Soft Tissue Sarcoma Phase II/III and the encouraging update from Head and Neck and Liver cancers Phase I/II trials. Indeed, the support of the European Investment Bank strengthens our balance sheet, which allows us to move forward with our 2019 upcoming key milestones.”

The unaudited1 consolidated financial statements for the fiscal year ended December 31, 2018 were approved by the executive board and reviewed by the supervisory board of the Company on March 15, 2019.

Consolidated Income statement (unaudited)1

K€   2018   2017
Total revenue and other income   3,479   3,722
Sales

Services

Other sales

Licences

 

Other revenues

Research Tax Credit

Subsidies

Other

  116

109

7

-

 

3,363

3,251

90

22

 

252

229

23

-

 

3,470

3,259

154

57

Research & Development (R&D) costs (incl.
Share-based payments)

(20,893) (17,733)

Selling, General and Administrative (SG&A)

Seite 1 von 5
Wertpapier
Nanobiotix
Mehr zum Thema
EuroFrancParisNanoESM


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel